Geneva, Oct. 9 -- International Clinical Trials Registry received information related to the study (NCT07854522) titled 'A Study of QL1706 Combined With OH2 Injection in Perioperative Treatment of Stage III Resectable Acral Melanoma' on Sept. 28.

Study Type: Interventional

Study Design: Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label).

Primary Sponsor: Peking University Cancer Hospital & Institute

Condition: Melanoma Acral Melanoma

Intervention: Drug: Iparomlimab and Tuvonralimab Injection (QL1706)

Recruitment Status: Not recruiting

Phase: Phase 4

Date of First Enrollment: October 2026

Target Sample Size: 76

To know more, visit https://clinicaltrials.g...